Illumina (NASDAQ:ILMN) Director Keith Meister Sells 119,501 Shares of Stock

05 Sep 2026, 10:52 by Mitch Edgeman · The Markets Daily

Illumina, Inc. (NASDAQ:ILMN – Get Free Report) Director Keith Meister sold 119,501 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $218.40, for a total value of $26,099,018.40. Following the sale, the director owned 770,350 shares of the company’s stock, valued at approximately $168,244,440. The trade was a 13.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Illumina Price Performance

Shares of Illumina stock opened at $218.22 on Friday. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $231.81. The stock has a market capitalization of $32.95 billion, a P/E ratio of 40.71, a PEG ratio of 3.14 and a beta of 1.46. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The business’s fifty day moving average price is $198.42 and its 200 day moving average price is $159.03.

Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current year.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Argus raised its price target for Illumina (ILMN) from $180 to $235 and upgraded the stock to “buy,” implying additional upside from recent levels. The bullish view reflects confidence in Illumina’s earnings outlook and continued demand for genomic sequencing.
Neutral Sentiment: Broader biotechnology coverage was mixed. 10x Genomics’ strong rally, supported by consumables growth and improved guidance, highlights investor interest in life-sciences tools, although weak instrument demand and valuation concerns remain sector risks. 10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
Neutral Sentiment: Articles about robotics and AI-focused ETFs may support long-term interest in technology and automation themes, but they do not represent a direct catalyst for Illumina’s business or stock. Are Robots the New Normal? Bet on these ETFs to Invest in the Future
Negative Sentiment: Zacks Research downgraded ILMN from “strong buy” to “hold.” The change introduces caution after the stock’s substantial advance and suggests that current valuation and expectations may leave less room for execution missteps. Illumina Analyst Downgrade
Negative Sentiment: PacBio’s reduced 2026 outlook, attributed to weaker instrument demand and slower clinical adoption, is a modest negative read-through for the sequencing market. Although PacBio is a competitor rather than an Illumina subsidiary, the update raises questions about the pace of demand across the industry. PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

Analyst Upgrades and Downgrades

Several research firms have issued reports on ILMN. Barclays boosted their price objective on shares of Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research note on Friday, July 31st. Canaccord Genuity Group boosted their price objective on Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research note on Monday, August 3rd. Citigroup increased their target price on Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research note on Monday, August 3rd. Guggenheim raised their price target on shares of Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a report on Friday, July 31st. Finally, Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Nine investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Illumina currently has an average rating of “Hold” and a consensus price target of $191.31.

Check Out Our Latest Report on ILMN

Hedge Funds Weigh In On Illumina

Several institutional investors and hedge funds have recently made changes to their positions in ILMN. BlackRock Inc. acquired a new stake in shares of Illumina in the 2nd quarter valued at about $3,374,423,000. Plato Investment Management Ltd bought a new position in shares of Illumina during the second quarter worth about $948,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Illumina in the second quarter worth about $30,501,000. Edmond DE Rothschild Holding S.A. acquired a new position in Illumina in the second quarter worth about $129,792,000. Finally, Impact Partnership Wealth LLC increased its holdings in Illumina by 235.8% in the first quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock valued at $1,366,000 after buying an additional 7,780 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Company Profile

(Get Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.